Do Plasma Anti Phospholipid Antibodies in Patients with Autoimmune Haemolytic Anaemia Correlate with Reduced Levels of Erythrocyte Complement Receptor 1?

References

• Siegel I., Liu T. L., Gleicher N. The red-cell immune system. Lancet 1981; ii: 556–559
   Google Scholar
• Ahearn J. M., Fearon D. T. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 1989; 46: 183–219
   PubMed Web of Science ®Google Scholar
• Ross G. D., Yount W. J., Walport M. J., Winfield J. B., Parker C. J., Fuller C. R., Taylor R. P., Myones B. L., Lachmann P. J. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J. Immunol. 1985; 135: 2005–2014
   PubMed Web of Science ®Google Scholar
• Walport M. J., Lachmann P. J. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arth. Rheum. 1988; 31: 153–158
   PubMed Web of Science ®Google Scholar
• Walport M. J., Ross G. D., Mackworth-Young C., Watson J. V., Hogg N., Lachmann P. J. Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin. exp. Immunol. 1985; 59: 547–554
   PubMed Web of Science ®Google Scholar
• Uko G., Dawkins R. L., Kay P., Christiansen F. T., Hollingsworth P. N. CR1 deficiency in SLE: acquired or genetic?. Clin. exp. Immunol. 1985; 62: 329–336
   PubMed Web of Science ®Google Scholar
• Walport M., Ng Y. C., Lachmann P. J. Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin. exp. Immunol. 1987; 69: 501–507
   PubMed Web of Science ®Google Scholar
• Degroot P. G., Oosting J. D., Derksen R. Antiphos-pholipid antibodies—specificity and pathophysiology. Baillieres Clinical Haematology 1993; 6: 691–709
   PubMed Web of Science ®Google Scholar
• Harris E. N., Chan J. K. H., Asherson R. A., Abert V. R., Gharavi A. E., Hughes G. R. V. Thrombosis, recurrent fetal loss, and thrombocytopenia. Arch. Intern. Med. 1986; 146: 2153–2156
   PubMedGoogle Scholar
• Hughes G. R. V., Harris E. N., Gharavi A. E. The anticardiolipin syndrome. J. Rheumatol 1986; 13: 486–489
   PubMed Web of Science ®Google Scholar
• Arvieux J., Roussel B., Ponard D., Colomb M. G. Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation. Clin. exp. Immunol. 1991; 84: 466–471
   PubMed Web of Science ®Google Scholar
• Corvetta A., Pomponio G., Bencivenga R., Luchetti M. M., Spycher M., Spaeth P. J., Danieli G. Low numbers of complement C3b/C4b receptors (CR1) on erythrocytes from patients with essential mixed cryoglobulinaemia, systemic lupus erythematosus and rheumatoid arthritis: relationship with disease activity, anticardiolipin antibodies, complement activation and therapy. J. Rheumatol 1991; 18: 1021–1025
   PubMed Web of Science ®Google Scholar
• Hammond A., Rudge A. C., Loizou S., Bowcock S. J., Walport M. J. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Arth. Rheum. 1989; 32: 259–264
   PubMed Web of Science ®Google Scholar
• Fong K. Y., Loizou S., Boey M. L., Walport M. J. Anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus. Br. J. Rheumatol 1992; 31: 453–455
   PubMedGoogle Scholar
• Guzmán J., Cabral A. R., Cabiedes J., Pita-Ramirez L., Alarcón-Segovia D. Antiphospholipid antibodies in patients with idiopathic autoimmune haemolytic anaemia. Autoimmunity 1994; 18: 51–56
   PubMed Web of Science ®Google Scholar
• Jones D. R. E., Thompson R. J., Rao S. A., Imrie H. An enzyme-linked immunosorbent assay for complement regulatory proteins and membrane-bound immunoglobulins on intact red cells. J. Immunol. Meth. 1994; 177: 235–242
   PubMed Web of Science ®Google Scholar
• Sokol R. J., Booker D. J., Stamps R. Erythrocyte antibodies, autoimmune haemolytic anaemia, and carcinoma. J. Clin. Pathol. 1994; 47: 340–343
   PubMed Web of Science ®Google Scholar
• Dacie J. V., Lewis S. M. Practical Haematology, 7th Edn. Churchill Livingstone, Edinburgh 1991; 538
   Google Scholar
• Pierangeli S. S., Harris E. N., Gharavi A. E., Goldsmith G., Branch D. W., Dean W. L. Are immunoglobulins with lupus anticoagulant activity specific for phospholipids?. Br. J. Haematol. 1993; 85: 124–132
   PubMed Web of Science ®Google Scholar
• Galli M., Comfurius P., Maasen C., Hemker H. C., de Baets M. H., van Breda-Vriesman P. J. C., Barbui T., Zwaal R. F. A., Bevers E. M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547
   PubMed Web of Science ®Google Scholar
• Jones J. V., James H., Tan M. H., Mansour M. Antiphospholipid antibodies require β2-glycoprotein I (Apolipoprotein H) as cofactor. J. Rheumatol 1992; 19: 1397–1402
   PubMed Web of Science ®Google Scholar
• Koike T., Matsuura E. What is the “true” antigen for anticardiolipin antibodies?. Lancet 1991; 337: 671–672
   PubMed Web of Science ®Google Scholar
• Hunt J. E., McNeil H. P., Crameri R., Morgan G., Krilis S. A. A phospholipid β2-glycoprotein complex is an antigen for antiphospholipid antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75–81
   PubMed Web of Science ®Google Scholar
• Hazeltine M., Rauch J., Danoff D., Esdaile J. M., Tannenbaum H. Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs' and hypocomplementemia. J. Rheumatol 1988; 15: 80–86
   PubMed Web of Science ®Google Scholar
• Sthoeger Z., Sthoeger D., Green L., Geltner D. The role of anticardiolipin autoantibodies in pathogenesis of autoimmune hemolytic anaemia in systemic lupus erythematosus. J. Rheumatol. 1993; 20: 2058–2061
   PubMed Web of Science ®Google Scholar
• Cabral A. R., Cabiedes J., Alarcón-Segovia D. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. J. Autoimmunity 1990; 3: 773–787
   PubMed Web of Science ®Google Scholar
• Arvieux J., Schweizer B., Roussel B., Colomb M. G. Autoimmune haemolytic anaemia due to anti-phospholipid antibodies. Vox Sang 1991; 61: 190–195
   PubMed Web of Science ®Google Scholar
• Manoussakis M. N., Tzioufas A. G., Silis M. P., Pange P. J. E., Goudevenos J., Moutsopoulos H. M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin. exp. Immunol. 1987; 69: 557–565
   PubMed Web of Science ®Google Scholar
• Fields R. A., Toubbeh H., Searles R. P., Bankhurst A. D. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J. Rheumatol 1989; 16: 623–625
   PubMed Web of Science ®Google Scholar
• Chakravarty K. K., Gray R. E. S., Webley M., Byron M. A., Wozniak J. Prevalence of anticardiolipin antibodies in the elderly British population. Postgrad. Med. J. 1991; 67: 358–361
   PubMed Web of Science ®Google Scholar
• Shapiro S., Kohn D., Miller B., Gershon H. Erythrocytes from young but not elderly donors can bind and degrade immune complex-and antibody-bound C3 in vitro. Clin. exp. Immunol. 1994; 95: 181–190
   PubMed Web of Science ®Google Scholar
• Wong W. W. Structural and functional correlation of the human complement receptor type 1. J. Invest. Dermatol. 1990; 94: 64S–67S
   PubMed Web of Science ®Google Scholar